Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
Retrieved on:
水曜日, 5月 15, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, MSD, HER2, BTC, Cisplatin, PBC, Brentuximab vedotin, HCC, INT, Merck & Co., Pros, Endometrial cancer, ADC, Abstract, Melanoma, Hepatocellular carcinoma, Physician, PD-L1, Quality of life (healthcare), TNBC, Pembrolizumab, Safety, NSCLC, Cancer, Carcinoma, ASCO, Society, Patient, AHCC, Lung cancer, Therapy, Radiation, Daiichi Sankyo, MRK, Conjugation, Webcast, Quality of life, Annual general meeting, Georgetown University, Pharmaceutical industry
New data being shared at the meeting showcase the company’s continued progress to advance clinical research for Merck’s broad portfolio and diverse pipeline of investigational candidates.
Key Points:
- New data being shared at the meeting showcase the company’s continued progress to advance clinical research for Merck’s broad portfolio and diverse pipeline of investigational candidates.
- “This year’s ASCO is also particularly meaningful as we approach 10 years since KEYTRUDA was first approved in the U.S.
- As Merck continues to build its broad oncology portfolio, the company will also present data at ASCO from its diverse pipeline of investigational candidates, many being evaluated in combination with KEYTRUDA.
- Merck will hold an Oncology Investor Event to coincide with the 2024 ASCO Annual Meeting on Monday, June 3, 2024, 6 p.m. CT, at which senior management will provide an update on the company’s oncology strategy and program.